| Ausstehende Aktien | 77,187,823 shares |
| Insider-Aktien | 27.921.493 shares |
| Insider-Besitz | 36,17 % |
| Insider gesamt | 49 |
Insider-Stimmungswert
Der Insider-Stimmungswert ermittelt die Unternehmen, die von Unternehmensinsidern gekauft werden.
Es ist das Ergebnis eines ausgeklügelten quantitativen Multifaktormodells, das die Unternehmen mit der höchsten Insiderakkumulation identifiziert. Das Scoring-Modell verwendet eine Kombination aus der Nettozahl der Insiderkäufe der letzten 90 Tage, der Gesamtzahl der gekauften Aktien als Prozentsatz des Streubesitzes und der Gesamtzahl der von Insidern gehaltenen Aktien. Die Zahl reicht von 0 bis 100, wobei höhere Zahlen ein höheres Maß an Insiderkäufen anzeigen als bei anderen Unternehmen und 50 den Durchschnitt darstellt.
Aktualisierungshäufigkeit: Täglich
Führungskräfte-Stimmungswert
Der Führungskräfte-Stimmungswert findet Unternehmen, die von Führungskräften des Unternehmens gekauft werden.
Per Definition sind Führungskräfte des Unternehmens Insider, aber im Gegensatz zu anderen Insidern (10%ige Aktionäre und Vorstandsmitglieder) arbeiten Führungskräfte täglich für das Unternehmen und verwenden beim Handel ihr eigenes Geld. (10%ige Aktionäre und Vorstandsmitglieder sind oft Fondsmanager, die das Geld anderer Leute verwalten.) Daher sind Insider-Geschäfte, die von Führungskräften getätigt werden, viel bedeutender und sollten entsprechend behandelt werden.
Wie der Insider-Stimmungswert ist auch der Führungskräfte-Stimmungswert das Ergebnis eines ausgeklügelten quantitativen Multifaktormodells, das die Unternehmen mit der höchsten Führungskräftekonzentration identifiziert.
Aktualisierungshäufigkeit: Täglich
Wichtige Insider-Kennzahlen
Diese Karte zeigt, wie das Unternehmen bei verschiedenen Insider-Kennzahlen abschneidet. Der Perzentil-Rang zeigt, wie dieses Unternehmen im Vergleich zu anderen Unternehmen auf den US-Märkten abschneidet. Höhere Ränge deuten auf eine bessere Situation hin.
Es ist beispielsweise allgemein anerkannt, dass Insiderkäufe ein positiver Indikator sind, so dass Unternehmen mit mehr Insiderkäufen besser abschneiden würden als Unternehmen mit weniger Insiderkäufen (oder sogar Insiderverkäufen).
Prozent des Streubesitzes von Insidern gekauft (Rang)
2555 out of 10752
Prozent des von Insidern gekauften Streubesitzes ist die Gesamtzahl der von Insidern gekauften Aktien abzüglich der Gesamtzahl der von Insidern in den letzten 90 Tagen verkauften Aktien, geteilt durch den gesamten Streubesitz und multipliziert mit 100.
Diagramm zum Insiderhandel
Eledon Pharmaceuticals, Inc. Insider-Trades sind in der folgenden Grafik dargestellt. Insider sind leitende Angestellte, Direktoren oder bedeutende Investoren in einem Unternehmen. Im Allgemeinen ist es für Insider illegal, auf der Grundlage von wesentlichen, nicht-öffentlichen Informationen mit Aktien ihrer Unternehmen zu handeln. Das bedeutet nicht, dass es für sie illegal ist, irgendwelche Geschäfte in ihren eigenen Unternehmen zu tätigen. Sie müssen jedoch alle Geschäfte der SEC über ein Formular 4 melden.
Kennzahlen zu Insiderlisten und Rentabilität
Diese Tabelle zeigt die Liste der bekannten Insider und wird automatisch aus den bei der SEC eingereichten Unterlagen erstellt. Zusätzlich zu den Namen, dem letzten Titel und der Bezeichnung als Direktor, leitender Angestellter oder 10%-iger Anteilseigner geben wir die zuletzt veröffentlichten Bestände an. Zusätzlich stellen wir, wenn möglich, die historische Handelsperformance für den Insider zur Verfügung. Die historische Handelsperformance ist ein gewichteter Durchschnitt der Performance tatsächlicher offener Kauftransaktionen, die von dem Insider getätigt wurden. Weitere Informationen zur Berechnung dieses Wertes finden Sie in diesem YouTube-Webinar.
See our leaderboard of most profitable insider traders.
| Insider | Durchschnittlicher Gewinn (%) | Aktien in Besitz |
Split Angepasst |
|---|---|---|---|
|
Apple Tree Partners Ii Lp
Director, 10% Owner -
[D]
|
4.218.641 | 4.218.641 | |
|
Apple Tree Partners II - Annex, L.P.
Director, 10% Owner -
[D]
|
3.568.438 | 3.568.438 | |
|
Apple Tree Partners IV, L.P.
Director, 10% Owner -
[D]
|
250.000 | 250.000 | |
| Timothy J Barberich Director - [D] | 121.077 | 121.077 | |
| Biotechnology Value Fund Ii Lp - | 113.152 | 220.460 | |
| Biotechnology Value Fund L P - | 113.152 | 220.460 | |
|
Bvf Gp Holdings Llc
10% Owner -
|
113.152 | 220.460 | |
| Bvf I Gp Llc - | 113.152 | 220.460 | |
| Bvf Ii Gp Llc - | 113.152 | 220.460 | |
|
Bvf Inc/il
10% Owner -
|
113.152 | 220.460 | |
|
Bvf Partners L P/il
10% Owner -
|
220.460 | 220.460 | |
| BVF Partners OS Ltd. - | 113.152 | 220.460 | |
| Biotechnology Value Trading Fund OS LP - | 113.152 | 220.460 | |
| Buckley Stephen Jr. Director - [D] | 11.000 | 11.000 | |
| Erez Chimovits Director - [D] | 3.183.314 | 3.183.314 | |
| Cheryl Cohen Director - [D] | 0 | 0 |
| Insider | Durchschnittlicher Gewinn (%) | Aktien in Besitz |
Split Angepasst |
|---|---|---|---|
| Flesher Gregory J. Chief Executive Officer, Director - [D] [O] | 156.918 | 156.918 | |
| Karen Jean Ferrante | 62.000 | ||
| David-Alexandre C Gros Chief Executive Officer, Director - [D] [O] | 9.000 | 9.000 | |
|
Seth Loring Harrison
Director, 10% Owner -
[D]
|
7.912.079 | 7.912.079 | |
| Jan Hillson Director - [D] | 3.430 | 3.430 | |
| Lee Kalowski Chief Financial Officer - [O] | 40.953 | 40.953 | |
| Keith Katkin Director - [D] | 8.575 | 8.575 | |
| Kessler David A. | 12.000 | ||
| Allan Kirk Director - [D] | 3.430 | 3.430 | |
| Jon Kuwahara See Remarks - [O] | 5.974 | 5.974 | |
|
Mark N Lampert
10% Owner -
|
113.152 | 220.460 | |
|
Lifesci Index Partners Llc
10% Owner -
|
1.065.867 | 1.065.867 | |
| Gary A Lyons Director - [D] | 0 | 0 | |
| June Lee Director - [D] | 3.430 | 3.430 | |
| Paul Sean Little CHIEF FINANCIAL OFFICER - [O] | 10.000 | 10.000 | |
|
Logos Global Management LP
10% Owner -
|
224.071 | 224.071 |
| Insider | Durchschnittlicher Gewinn (%) | Aktien in Besitz |
Split Angepasst |
|---|---|---|---|
| McBride John S. Director - [D] | 3.430 | 3.430 | |
| Jodie Pope Morrison President and CEO, Director - [D] [O] | 57.566 | 57.566 | |
|
Ag Novartis
10% Owner -
|
4.493.458 | 4.493.458 | |
|
Bioventures Ltd Novartis
10% Owner -
|
4.493.458 | 4.493.458 | |
| Christine Ocampo See Remarks - [O] | 23.160 | 23.160 | |
| Walter C Ogier | 20.000 | ||
|
OrbiMed Israel BioFund GP Limited Partnership
Director, 10% Owner -
[D]
|
73.650 | 73.650 | |
|
OrbiMed Israel GP Ltd.
10% Owner -
|
73.650 | 73.650 | |
| Steven Perrin President, Director - [D] [O] | 1.000 | 1.000 | |
| Gerald E Quirk | 62.000 | ||
| Robinson James A. Jr. Director - [D] | 3.430 | 3.430 | |
|
Muneer A Satter
10% Owner -
|
1.771.688 | 1.771.688 | |
| Smith Bryan E. | 120.000 | ||
| Turkel Catherine C. President - [O] | 88.662 | 88.662 | |
|
Martin D Williams
10% Owner -
|
337.700 | 337.700 | |
|
Paul Yook
10% Owner -
|
1.065.867 | 1.065.867 | |
| Yanchik Joseph A., III Director - [D] | 51.092 | 51.092 |
Report errors via our new Insider Auditing Tool
Erfolgsbilanz der Insiderkäufe - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in ELDN / Eledon Pharmaceuticals, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch .
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
Bereinigter Preis ist der splitbereinigte Preis. Bereinigte Aktien sind die um den Split bereinigten Aktien.
Erfolgsbilanz von Insiderverkäufen - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in ELDN / Eledon Pharmaceuticals, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch .
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
Bereinigter Preis ist der splitbereinigte Preis. Bereinigte Aktien sind die um den Split bereinigten Aktien.
Transaktionshistorie
Klicken Sie auf das Link-Symbol, um den vollständigen Transaktionsverlauf anzuzeigen. Transaktionen, die im Rahmen eines automatischen Handelsplans 10b5-1 gemeldet werden, sind in der Spalte 10b-5 mit einem X gekennzeichnet.
| Datei Datum |
Handel Datum |
Form | Insider | Ticker | Wertpapier-Titel | Code | Direkt | Ausführung Preis |
Einheit Preis |
Eimheiten Verändert |
Wert Geändert (1K) |
Verbleibende Optionen |
Verbleibende Aktien |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-16 | 2026-01-10 | 4 | Robinson James A. Jr. | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Lee June | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Katkin Keith | ELDN | Common Stock | D | 8.575 | 8.575 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Kirk Allan | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Hillson Jan | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | McBride John S. | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 75.431 | 220.460 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 821.121 | 2.633.679 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1.031.385 | 3.361.803 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 86.341 | 145.029 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 837.146 | 1.812.558 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1.055.445 | 2.330.418 | ||||||
| 2022-11-23 | 2022-11-23 | 4 | Perrin Steven | ELDN | Common Stock | D | 2,5969 | 1.000 | 3 | 1.000 | ||||
| 2022-02-02 | 2022-02-01 | 4 | Gros David-Alexandre C | ELDN | Stock Option (right to buy) | D | 3,97 | 108.000 | 108.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Smith Bryan E. | ELDN | Stock Option (right to buy) | D | 3,97 | 120.000 | 120.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Ogier Walter C | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Perrin Steven | ELDN | Stock Option (right to buy) | D | 3,97 | 155.000 | 155.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | McBride John S. | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | LYONS GARY A | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Lee June | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Hillson Jan | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Katkin Keith | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Little Paul Sean | ELDN | Stock Option (right to buy) | D | 3,97 | 155.000 | 155.000 | |||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 975.412 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 1.274.973 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 58.688 | ||||||||
| 2021-12-21 | 2021-12-20 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 4,4800 | 2.000 | 9 | 9.000 | ||||
| 2021-08-19 | 2021-08-17 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 6,2100 | 4.000 | 25 | 7.000 | ||||
| 2021-06-14 | 2021-06-11 | 4 | Little Paul Sean | ELDN | Common Stock | D | 8,8700 | 10.000 | 89 | 10.000 | ||||
| 2021-06-10 | 2021-06-09 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 8,0100 | 3.000 | 24 | 3.000 | ||||
| 2021-05-04 | 2021-05-03 | 4 | Smith Bryan E. | ELDN | Stock Option (Right to Buy) | D | 9,91 | 158.500 | 158.500 | |||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -1.757 | 6.758 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -9.169 | 39.693 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -11.776 | 52.145 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -35 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -203 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -273 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 97.615 | 113.152 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 1.944 | 15.537 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 509.410 | 598.624 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 11.278 | 89.214 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 654.215 | 771.780 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 15.166 | 117.565 | ||||||
| 2020-12-04 | 2020-12-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 21,6000 | -103.200 | -2.229 | 73.650 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,5507 | 9.098 | 232 | 224.071 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,1740 | 15.000 | 393 | 214.973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 27,0200 | -27 | -1 | 199.973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,8790 | 12.942 | 335 | 200.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,6442 | -12.942 | -345 | 187.058 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,4824 | 15.000 | 397 | 200.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,9730 | 4.000 | 104 | 185.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24,5299 | 31.000 | 760 | 181.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24,0325 | 5.000 | 120 | 150.000 | ||||
| 2020-11-06 | 3 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 145.000 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 77.936 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 102.400 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 13.595 | ||||||||
| 2020-09-15 | 2020-09-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 500,00 | 1.167 | 1.167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 500,00 | 1.167 | 1.167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 500,00 | 2.145 | 2.145 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 500,00 | 5.907 | 5.907 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Gros David-Alexandre C | NVUS | Stock Option (Right to Buy) | D | 500,00 | 18.278 | 18.278 | |||||
| 2020-03-20 | 2020-03-19 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0,26 | 50.000 | 50.000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0,26 | 100.000 | 100.000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0,26 | 200.000 | 200.000 | |||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | |||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | |||||
| 2019-09-30 | 2019-09-26 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0,67 | 100.000 | 100.000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0,67 | 75.000 | 75.000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0,67 | 60.000 | 60.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Chimovits Erez | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-05-22 | 2019-05-21 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1,9114 | -2.937 | -6 | 156.918 | ||||
| 2019-05-22 | 2019-05-20 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1,9616 | -11.701 | -23 | 159.855 | ||||
| 2019-05-22 | 2019-05-21 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1,9114 | -1.058 | -2 | 5.974 | ||||
| 2019-05-22 | 2019-05-20 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1,9616 | -4.218 | -8 | 7.032 | ||||
| 2019-05-22 | 2019-05-21 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1,9114 | -1.914 | -4 | 88.662 | ||||
| 2019-05-22 | 2019-05-20 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1,9616 | -7.623 | -15 | 90.576 | ||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez | NVUS | Common Stock | I | 3,1000 | 646.204 | 2.003 | 3.183.314 | ||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 3,1000 | 646.204 | 2.003 | 3.183.314 | ||||
| 2019-05-02 | 2019-04-30 | 4 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, par value $0.01 per share | I | 2,7000 | -200 | -1 | 1.065.867 | ||||
| 2019-03-18 | 2019-03-14 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 3,72 | 25.000 | 25.000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 3,72 | 90.000 | 90.000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 25.000 | 171.556 | ||||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 3,72 | 50.000 | 50.000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20.000 | 98.199 | ||||||
| 2018-09-13 | 2018-09-12 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 5,0190 | 16.632 | 83 | 78.199 | ||||
| 2018-09-13 | 2018-09-11 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 4,5560 | 17.048 | 78 | 61.567 | ||||
| 2018-09-07 | 2018-09-05 | 4 | TURKEL CATHERINE C. By Spouse's IRA | NVUS | Common Stock | I | 3,9660 | 805 | 3 | 805 | ||||
| 2018-06-14 | 2018-06-13 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4,83 | 24.000 | 24.000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20.000 | 44.519 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 4,83 | 56.500 | 56.500 | |||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 30.700 | 146.556 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 4,83 | 12.000 | 12.000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 11.250 | 11.250 | ||||||
| 2017-11-06 | 2017-11-06 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4,21 | 50.000 | 50.000 | |||||
| 2017-07-10 | 2017-07-10 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 5,61 | 35.000 | 35.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 5,85 | 36.000 | 36.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Morrison Jodie Pope | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-05-26 | 2017-05-24 | 4 | OCAMPO CHRISTINE | NVUS | Stock Option (Right to Buy) | D | 5,50 | 52.500 | 52.500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 5,50 | 52.500 | 52.500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 5,50 | 250.000 | 250.000 | |||||
| 2017-05-11 | 3 | LYONS GARY A | NVUS | No Securities Owned | D | 0 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113.794 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113.794 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26.816 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26.816 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24.238 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24.238 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23.160 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23.160 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5.074.220 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5.074.220 | ||||||||
| 2017-05-11 | 2017-05-10 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 9,9900 | 58.959 | 589 | 115.856 | ||||
| 2017-05-11 | 2017-05-10 | 4 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 9,9900 | 10.010 | 100 | 21.590 | ||||
| 2017-05-11 | 2017-05-10 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 9,9900 | 11.111 | 111 | 24.519 | ||||
| 2017-05-11 | 2017-05-09 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 2.537.110 | 2.537.110 | ||||||
| 2016-06-16 | 2016-06-15 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-16 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-03-15 | 2016-03-15 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 5,7400 | 8.000 | 46 | 11.000 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,37 | -20.000 | 37.878 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -8.015 | 0 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,3700 | 20.000 | 27 | 57.566 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 8.015 | 5 | 37.566 | ||||
| 2015-12-17 | 2015-12-15 | 4 | Ferrante Karen Jean | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 9,65 | 189.000 | 189.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-11-12 | 2015-11-11 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 11,2500 | 3.000 | 34 | 3.000 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -13.500 | 186.678 | |||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0100 | -13.500 | -189 | 0 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 13.500 | 57 | 13.500 | ||||
| 2015-09-08 | 2015-09-08 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13,1300 | -4.668 | -61 | 40.953 | ||||
| 2015-09-04 | 2015-09-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 12,9600 | -2.158 | -28 | 45.621 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,37 | -3.000 | 57.878 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -7.000 | 8.015 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -564 | 312.736 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,3700 | 3.000 | 4 | 29.551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 7.000 | 4 | 26.551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -564 | -8 | 19.551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 564 | 1 | 20.115 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -12.000 | 313.300 | |||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -12.000 | -164 | 19.551 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 12.000 | 19 | 31.551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -7.426 | 15.015 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 2,31 | -2.574 | 0 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 7.426 | 5 | 19.551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 2,3100 | 2.574 | 6 | 12.125 | ||||
| 2015-07-17 | 2015-07-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2580 | -3.566 | -51 | 4.493.458 | ||||
| 2015-07-15 | 2015-07-14 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,4100 | -27.861 | -401 | 4.497.024 | ||||
| 2015-07-15 | 2015-07-13 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2020 | -20.611 | -293 | 4.524.885 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -8.000 | 325.300 | |||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -8.000 | -110 | 9.551 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 8.000 | 13 | 17.551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -8.000 | 333.300 | |||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,8300 | -8.000 | -111 | 9.551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 8.000 | 13 | 17.551 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -300 | 200.178 | |||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 14,2000 | -300 | -4 | 0 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 300 | 1 | 300 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -6.700 | 200.478 | |||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0000 | -6.700 | -94 | 0 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 6.700 | 28 | 6.700 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -2.000 | 207.178 | |||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0200 | -2.000 | -28 | 0 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 2.000 | 8 | 2.000 | ||||
| 2015-06-19 | 2015-06-17 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-18 | 2015-06-16 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2700 | -1.120 | -16 | 4.545.496 | ||||
| 2015-06-16 | 2015-06-12 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -5.919 | -84 | 4.561.393 | ||||
| 2015-06-16 | 2014-06-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -14.777 | -210 | 4.546.616 | ||||
| 2015-06-12 | 2015-06-11 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -27.875 | -396 | 4.567.312 | ||||
| 2015-05-28 | 2015-05-26 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 10,81 | 214.605 | 214.605 | |||||
| 2015-04-20 | 2015-04-16 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13,0000 | -4.567 | -59 | 47.779 | ||||
| 2015-04-13 | 3 | Cohen Cheryl | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-04-13 | 2015-04-09 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 11,08 | 25.000 | 25.000 | |||||
| 2015-04-06 | 2015-04-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 11,4500 | -2.258 | -26 | 52.346 | ||||
| 2015-03-20 | 2015-03-19 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,5000 | -46.141 | -669 | 4.595.187 | ||||
| 2015-03-20 | 2015-03-18 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,5000 | -3.000 | -44 | 4.641.328 | ||||
| 2015-01-12 | 3 | Buckley Stephen Jr. | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-01-12 | 2015-01-08 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14,49 | 25.000 | 25.000 | |||||
| 2014-10-17 | 2014-10-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 13,25 | 134.134 | 134.134 | |||||
| 2014-10-17 | 2014-10-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 13,25 | 50.671 | 50.671 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series E Preferred Stock | I | -8.013.003 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-3 Preferred Stock | I | -3.931.085 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-2 Preferred Stock | I | -457.728 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-1 Preferred Stock | I | -4.577.315 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 15,0000 | 150.000 | 2.250 | 1.771.688 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 1.621.688 | 1.621.688 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series E Preferred Stock | I | -24.199.308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-3 Preferred Stock | I | -24.046.035 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-2 Preferred Stock | I | -1.539.643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-1 Preferred Stock | I | -8.711.335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series C Preferred Stock | I | -14.604.833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-2 Preferred Stock | I | -644.786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-1 Preferred Stock | I | -798.067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series A Preferred Stock | I | -4.500.000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 15,0000 | 362.500 | 5.438 | 7.912.079 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 7.549.570 | 7.549.579 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series E Preferred Stock | D | -24.199.308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series D-3 Preferred Stock | D | -10.675.613 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 15,0000 | 237.500 | 3.562 | 3.568.438 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 3.330.938 | 3.330.938 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | 165.251 | 165.251 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series E Preferred Stock | D | -15.064.469 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-3 Preferred Stock | D | -13.222.826 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-2 Preferred Stock | D | -1.539.643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-1 Preferred Stock | D | -15.396.431 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 15,0000 | 325.000 | 4.875 | 4.644.328 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 4.319.328 | 4.319.328 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series E Preferred Stock | D | -809.955 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series D-3 Preferred Stock | D | -457.731 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Common Stock | D | 121.077 | 121.077 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-3 Preferred Stock | D | -13.370.422 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-2 Preferred Stock | D | -1.539.643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-1 Preferred Stock | D | -8.711.335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series C Preferred Stock | D | -14.604.833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-2 Preferred Stock | D | -644.786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-1 Preferred Stock | D | -798.067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series A Preferred Stock | D | -4.500.000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 4.218.632 | 4.218.641 | ||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250.000 | ||||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250.000 | ||||||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 15,00 | 218.417 | 218.417 | |||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Common Stock | D | 54.604 | 54.604 | ||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19.102 | ||||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19.102 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51.092 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51.092 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337.700 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337.700 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212.712 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425.397 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212.712 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425.397 |
P
Offener Markt oder privater Kauf von nicht-derivativen oder derivativen Wertpapieren
S
Freiverkauf oder privater Verkauf von nicht-derivativen oder derivativen Wertpapieren
A
Gewährung, Vergabe oder sonstiger Erwerb von Wertpapieren des Unternehmens (z. B. eine Option)
C
Umwandlung von Derivaten
D
Verkauf oder Rückübertragung von Wertpapieren an das Unternehmen
F
Zahlung des Ausübungspreises oder der Steuerschuld mit einem Teil der vom Unternehmen erhaltenen Wertpapiere
G
Schenkung von Wertpapieren durch oder an den Insider
K
Aktien-Swaps und ähnliche Absicherungstransaktionen
M
Ausübung oder Umwandlung eines vom Unternehmen erhaltenen derivativen Wertpapiers (z. B. einer Option)
V
Eine freiwillig auf Formular 4 gemeldete Transaktion
J
Sonstige (mit einer Fußnote zur Beschreibung der Transaktion)
